Centers for Disease Control and Prevention

National Center for Immunization and Respiratory DiseasesPhotographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation 

use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences.

Adult Respiratory Syncytial Virus (RSV) SesCamille Kotton, MDChair, Adult RSV Work GroupAdvisory Committee on Immunization Practices (ACIP)October 25, 2023
RSVPreF3 (Arexvy, GSK) is a 1-dose adjuvanted (AS

recombinant prefusion F protein (preF) vaccine. 

RSVpreF (Abrysvo, Pfizer) is a 1-dose recombinant pIn June 2023, CDC’s Advisory Committee on ImmPractices (ACIP) voted to recommend that adultyears and older may receive a single dose of RSV using shared clinical decision making. https://www.cdc.gov/mmwr/volumes/72/wr/mm7229a4.htm
 The Work Group reviewed CDC vaccine safety surveillance plans for R

adults ≥60 years.

 GSK shared with the Work Group results of an immuno-bridging study 

inferior humoral immune responses to RSV vaccination in immunocom50–59, compared with immunocompetent adults ≥60 (in whom efficademonstrated).

 The Work Group discussed the potential role of RSV vaccination in ad

60 years, including subpopulations that would benefit most from vaccequity implications.

Issues under discussion since the June meet
 The Work Group reviewed CDC vaccine safety surveillance plans fo

vaccination in adults ≥60 years. – V-safe (https://vsafe.cdc.gov) has launched for older adult RSV vacc– Today’s session will not include RSV vaccine uptake data or safety s

data are premature this early into the vaccination program – Uptake and safety results will be shared at a future ACIP meeting

Issues under discussion since the June meet
Agenda: Wednesday October 25, 2023

 RSVPreF3 safety and immunogenicity in adults aged 

50–59 years, compared with adults aged ≥60 years

 Epidemiology of RSV hospitalization in adults, with a 

focus on adults aged 50–59 years

 Work Group considerations regarding RSV 

vaccination in adults aged 50–59 years

Dr. Susan Dr. MonicDr. Amad
Adult RSV Work Group Membership

ACIP Voting MembersCamille Kotton (Chair)Keipp TalbotSarah LongEx Officio MembersRachel Zhang (FDA)Judy Beeler (FDA)Nicholas Geagan (FDA)Nadine Peart Akindele (FDA)Sonnie Kim (NIH/NIAID)Jeffrey Kelman (CMS)Michelle Juaneza (HRSA/VICP)Uzo Chukwuma (IHS)Valerie Marshal (OIDP)

Consultants

Robert Atmar (Baylor Coll. of Medicine)Helen Chu (U Washington)Peter Donofrio (Vanderbilt University)Marie Griffin (Vanderbilt University)Cynthia Lucero-Obusan (VHA)

Tracy Ruckwardt (NJonathan Temte (U Rebecca Morgan (CDoug Campos-Out

LiaisonsKenneth Schmader (AGS)Vidya Sundareshan (ACP)Gretchen LaSalle (AAFP)April Killikelly (NACI/PHAC)Winnie Su (NACI/PHAC)

Katherine Williams (ARuth Lynfield (NFID)Bindy Crouch (AIM)Steven Pergam (IDSA)Elizabeth Skoy (APhA)
CDC Contributors

Amadea Britton (co-lead)Michael Melgar (co-lead)Lauren RoperFiona Havers Chris TaylorMonica PattonMeredith McMorrowDiya SurieJennifer DeCuirMila PrillMonica GodfreyRuth Link-Gelles

Amanda PayneDanielle MouliaMegan WallaceNatalie ThornburgMelissa CoughlinJefferson JonesKatherine Fleming-DutraIsmael Ortega SanchezNoelle MolinariPragna PatelAron HallHannah Rosenblum

Derrell PowersRaigan WheelerJarrett GartinElizabeth GreeneManisha PatelLisa GrohskopfAnne HauseDavid ShayChristine OlsonTom ShimabukuroKaren BroderNeil Murthy

Patricia WoAndrew LeJamison PiSarah MeyNicole Dow
For more information, contact CDC

1-800-CDC-INFO (232-4636)TTY: 1-888-232-6348 www.cdc.govThe findings and conclusions in this report are those of the authors and do not necessarily represent the official 

position of the Centers for Disease Control and Prevention.Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences.